Assembling intelligence…
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS (POP: 1/25/2019 - 1/24/2024)
| Company | Orders | Obligated | Latest order end |
|---|---|---|---|
| THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 13 | $13.8M | 2027-05-31 |
| 75N91023F00001 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $1.3M | 2026-12-25 |
| 75N91023F00003 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $1.3M | 2027-03-14 |
| 75N91023F00002 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $1.2M | 2026-10-25 |
| 75N91019F00132 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $1.2M | 2023-06-14 |
| 75N91020F00002 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $1.2M |
| 2023-12-20 |